X4 Pharmaceuticals (XFOR) Cash from Investing Activities (2017 - 2025)

X4 Pharmaceuticals (XFOR) has 9 years of Cash from Investing Activities data on file, last reported at $16.8 million in Q4 2025.

• Quarterly Cash from Investing Activities rose 295.44% year-over-year to $16.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $8.2 million (down 87.83% YoY) and the FY2025 annual result came in at $8.2 million, down 87.83% from the prior year.
• Cash from Investing Activities improved to $16.8 million in Q4 2025, from -$28.7 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $96.9 million in Q2 2024 to a low of -$28.7 million in Q3 2025.
• A 5-year average of $3.0 million and a median of -$62000.0 in 2021 frame the typical range for Cash from Investing Activities.
• The widest YoY moves for Cash from Investing Activities: up 2083.25% in 2024, down 59033.33% in 2024.
• Tracing XFOR's Cash from Investing Activities over 5 years: stood at -$13000.0 in 2021, then slumped by 161.54% to -$34000.0 in 2022, then plunged by 14114.71% to -$4.8 million in 2023, then tumbled by 78.38% to -$8.6 million in 2024, then soared by 295.44% to $16.8 million in 2025.
• The last three Cash from Investing Activities figures came in at $16.8 million (Q4 2025), -$28.7 million (Q3 2025), and $23.1 million (Q2 2025), per Business Quant data.